Attention investors who purchased shares of HemaCare Corporation before December 16, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of HemaCare Corporation concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Charles River Laboratories International, Inc. for approximately $380 million.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors HemaCare Corporation (“HemaCare” or the “Company”) (OTC Pink: HEMA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Charles River Laboratories International, Inc. (“Charles River Laboratories”) (NYSE: CRL) in a transaction valued at approximately $380 million. Under the terms of the agreement, shareholders of HemaCare will receive $25.40 in cash for each share of HemaCare they own.
If you own common stock of HemaCare and purchased any shares before December 16, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.